First Time Loading...

Aura Biosciences Inc
NASDAQ:AURA

Watchlist Manager
Aura Biosciences Inc Logo
Aura Biosciences Inc
NASDAQ:AURA
Watchlist
Price: 7.06 USD 0.43% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

AURA's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Aura Biosciences, Inc. is a clinical-stage oncology company. [ Read More ]

The intrinsic value of one AURA stock under the Base Case scenario is 4.58 USD. Compared to the current market price of 7.06 USD, Aura Biosciences Inc is Overvalued by 35%.

Key Points:
AURA Intrinsic Value
Base Case
4.58 USD
Overvaluation 35%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Aura Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AURA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Aura Biosciences Inc

Provide an overview of the primary business activities
of Aura Biosciences Inc.

What unique competitive advantages
does Aura Biosciences Inc hold over its rivals?

What risks and challenges
does Aura Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in Aura Biosciences Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aura Biosciences Inc.

Provide P/S
for Aura Biosciences Inc.

Provide P/E
for Aura Biosciences Inc.

Provide P/OCF
for Aura Biosciences Inc.

Provide P/FCFE
for Aura Biosciences Inc.

Provide P/B
for Aura Biosciences Inc.

Provide EV/S
for Aura Biosciences Inc.

Provide EV/GP
for Aura Biosciences Inc.

Provide EV/EBITDA
for Aura Biosciences Inc.

Provide EV/EBIT
for Aura Biosciences Inc.

Provide EV/OCF
for Aura Biosciences Inc.

Provide EV/FCFF
for Aura Biosciences Inc.

Provide EV/IC
for Aura Biosciences Inc.

Show me price targets
for Aura Biosciences Inc made by professional analysts.

What are the Revenue projections
for Aura Biosciences Inc?

How accurate were the past Revenue estimates
for Aura Biosciences Inc?

What are the Net Income projections
for Aura Biosciences Inc?

How accurate were the past Net Income estimates
for Aura Biosciences Inc?

What are the EPS projections
for Aura Biosciences Inc?

How accurate were the past EPS estimates
for Aura Biosciences Inc?

What are the EBIT projections
for Aura Biosciences Inc?

How accurate were the past EBIT estimates
for Aura Biosciences Inc?

Compare the revenue forecasts
for Aura Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aura Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aura Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aura Biosciences Inc compared to its peers.

Compare the P/E ratios
of Aura Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aura Biosciences Inc with its peers.

Analyze the financial leverage
of Aura Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Aura Biosciences Inc.

Provide ROE
for Aura Biosciences Inc.

Provide ROA
for Aura Biosciences Inc.

Provide ROIC
for Aura Biosciences Inc.

Provide ROCE
for Aura Biosciences Inc.

Provide Gross Margin
for Aura Biosciences Inc.

Provide Operating Margin
for Aura Biosciences Inc.

Provide Net Margin
for Aura Biosciences Inc.

Provide FCF Margin
for Aura Biosciences Inc.

Show all solvency ratios
for Aura Biosciences Inc.

Provide D/E Ratio
for Aura Biosciences Inc.

Provide D/A Ratio
for Aura Biosciences Inc.

Provide Interest Coverage Ratio
for Aura Biosciences Inc.

Provide Altman Z-Score Ratio
for Aura Biosciences Inc.

Provide Quick Ratio
for Aura Biosciences Inc.

Provide Current Ratio
for Aura Biosciences Inc.

Provide Cash Ratio
for Aura Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Aura Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Aura Biosciences Inc?

What is the current Free Cash Flow
of Aura Biosciences Inc?

Financials

Balance Sheet Decomposition
Aura Biosciences Inc

Current Assets 231.8m
Cash & Short-Term Investments 226.2m
Other Current Assets 5.6m
Non-Current Assets 23.3m
PP&E 22m
Other Non-Current Assets 1.3m
Current Liabilities 12.4m
Accounts Payable 1.8m
Accrued Liabilities 9.6m
Other Current Liabilities 935k
Non-Current Liabilities 16.9m
Other Non-Current Liabilities 16.9m
Efficiency

Earnings Waterfall
Aura Biosciences Inc

Revenue
0 USD
Operating Expenses
-85m USD
Operating Income
-85m USD
Other Expenses
8.6m USD
Net Income
-76.4m USD

Free Cash Flow Analysis
Aura Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

AURA Profitability Score
Profitability Due Diligence

Aura Biosciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Aura Biosciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

AURA Solvency Score
Solvency Due Diligence

Aura Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Aura Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AURA Price Targets Summary
Aura Biosciences Inc

Wall Street analysts forecast AURA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AURA is 20.2 USD with a low forecast of 19.19 USD and a high forecast of 22.05 USD.

Lowest
Price Target
19.19 USD
172% Upside
Average
Price Target
20.2 USD
186% Upside
Highest
Price Target
22.05 USD
212% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AURA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AURA Price
Aura Biosciences Inc

1M 1M
-6%
6M 6M
-17%
1Y 1Y
-19%
3Y 3Y
-52%
5Y 5Y
-52%
10Y 10Y
-52%
Annual Price Range
7.06
52w Low
7.02
52w High
13.33
Price Metrics
Average Annual Return -8.13%
Standard Deviation of Annual Returns 49.62%
Max Drawdown -72%
Shares Statistics
Market Capitalization 348.4m USD
Shares Outstanding 49 350 800
Percentage of Shares Shorted 6.75%

AURA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Aura Biosciences Inc Logo
Aura Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

348.4m USD

Dividend Yield

0%

Description

Aura Biosciences, Inc. is a clinical-stage oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2021-10-29. The firm operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The firm's VDC platform offers a range of portfolio of targeted oncology therapeutics. The company engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).

Contact

MASSACHUSETTS
Cambridge
85 Bolton St
+16175008864.0
http://www.aurabiosciences.com/

IPO

2021-10-29

Employees

52

Officers

Founder, CEO, President & Director
Dr. Elisabet de los Pinos Ph.D.
CFO, Secretary & Treasurer
Ms. Julie B. Feder
Senior Vice President of Clinical Development Operations
Mr. Patrick Nealon
Senior VP & Therapeutic Area Head of Urologic Oncology
Dr. Bruce Brown M.D.
Therapeutic Area Head of Ocular Oncology
Dr. Anthony Daniels M.D.
Senior Vice President of Regulatory Affairs & Quality
Dr. Richard Mountfield Ph.D.

See Also

Discover More
What is the Intrinsic Value of one AURA stock?

The intrinsic value of one AURA stock under the Base Case scenario is 4.58 USD.

Is AURA stock undervalued or overvalued?

Compared to the current market price of 7.06 USD, Aura Biosciences Inc is Overvalued by 35%.